About
Constructive Bio is a Cambridge, UK-based synthetic biology company pioneering a dual-technology platform that combines de novo whole genome synthesis with engineered translation to create biologics of unprecedented precision. At its core is Syn61 — the world's first fully synthetic recoded genome — which frees up codons in the genetic code to encode non-canonical amino acids (ncAAs), chemical building blocks beyond nature's standard 20. The platform organizes ncAAs into three functional categories: Transformers (enabling novel reactivity such as covalent biologics and non-native tertiary structures), Enhancers (delivering site-specific conjugation, protease resistance, and targeted post-translational modifications), and Modulators (fine-tuning hydrophobicity, solubility, and stability). This programmable approach enables a wide range of therapeutic applications: GLP-1 and metabolic disease peptides with enhanced stability, homogeneous site-specific antibody-drug conjugates, irreversible covalent biologics, and complex modular assemblies like immunocytokines. Constructive Bio's manufacturing backbone runs on scalable E. coli and CHO fermentation, supporting production from milligrams to kilograms. The science is grounded in peer-reviewed publications in Nature, Science, and Nature Chemistry from Professor Jason Chin FRS. The company partners with pharmaceutical and biotech organizations seeking to develop therapeutics with chemistries previously inaccessible through traditional biological manufacturing.
Key Features
- Syn61 Synthetic Recoded Genome: The world's first fully synthetic recoded genome with over 4 million base pairs synthesized, freeing genetic codons to encode non-canonical amino acids at precise positions.
- Non-Canonical Amino Acid (ncAA) Library: Hundreds of exotic chemistries spanning Transformers, Enhancers, and Modulators that deliver new functions, enhanced control, and fine-tuned performance impossible with standard biology.
- Scalable Biomanufacturing: End-to-end fermentation-based manufacturing in E. coli and CHO with complete backbone flexibility from milligrams to kilogram-scale production.
- Genetically Encoded Precision: Entire genomes are rewritten to reprogram the genetic code, ensuring every ncAA modification is placed exactly as specified with unparalleled reliability.
- Multi-ncAA Incorporation: Supports incorporation of multiple non-canonical amino acids in a single peptide or protein molecule, enabling complex, multi-functional therapeutic assemblies.
Use Cases
- Developing next-generation GLP-1 receptor agonist peptides with enhanced metabolic stability and efficacy for obesity and type 2 diabetes treatment
- Creating homogeneous site-specific antibody-drug conjugates with optimized drug-antibody ratios for oncology applications
- Engineering covalent biologics with reactive handles for irreversible target engagement in hard-to-drug disease areas
- Building modular immunocytokine assemblies using click-chemistry enabled multi-functional therapeutic architectures
- Advancing synthetic biology research programs requiring precise incorporation of exotic chemistries into sequence-defined biopolymers
Pros
- Unmatched Chemical Diversity: Access to hundreds of ncAA chemistries unlocks therapeutic properties — such as covalent binding, protease resistance, and click-chemistry conjugation — that are impossible with natural biology.
- Scalable & Sustainable Manufacturing: Fermentation-based production in standard microbial and mammalian cell systems makes scale-up straightforward and commercially viable from early development to full production.
- Peer-Reviewed Scientific Foundation: The platform is built on 18+ publications in top journals including Nature and Science, providing strong credibility and de-risked technology for partners.
- Broad Therapeutic Applicability: Applicable across GLP-1 peptides, antibody-drug conjugates, covalent biologics, and complex immunocytokines, covering a wide range of therapeutic modalities.
Cons
- Highly Specialized & Early-Stage: The platform is cutting-edge but still emerging, meaning partners may face longer timelines and regulatory uncertainty compared to established therapeutic modalities.
- Partnership-Only Access: The technology is not available as a self-serve tool; access requires entering a formal partnership or licensing arrangement with the company.
- Narrow Target Audience: Relevant only to pharmaceutical, biotech, and research organizations with sophisticated drug development programs — not applicable to most general technology users.
Frequently Asked Questions
What is genetic code expansion?
Genetic code expansion is the process of rewriting an organism's genetic code to free up codons that normally encode redundant amino acids, then reprogramming those codons to incorporate non-canonical amino acids (ncAAs) — chemical building blocks beyond the standard 20 used by nature.
What is Syn61 and why is it significant?
Syn61 is the world's first fully synthetic recoded genome, containing over 4 million synthesized base pairs. By compressing the genetic code from 64 to 61 codons, it frees up slots that Constructive Bio reprograms to encode ncAAs, enabling the production of biologics with entirely new chemical properties.
What types of therapeutics can be created on the platform?
The platform supports a wide range of therapeutics including stabilized GLP-1 peptides for metabolic diseases, site-specific antibody-drug conjugates, covalent biologics with irreversible target engagement, and complex modular assemblies such as immunocytokines.
How does Constructive Bio manufacture its therapeutics?
Therapeutics are produced through fermentation using standard E. coli and CHO cell systems, enabling scalable, sustainable biomanufacturing from milligram research quantities up to kilogram-scale commercial production.
How can organizations partner with Constructive Bio?
Pharmaceutical and biotech companies can partner with Constructive Bio to co-develop therapeutics leveraging the ncAA platform. Interested parties can reach out via the company's website to explore partnership, licensing, or investment opportunities.
